Overview
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The Company’s pipeline of product candidates is designed with the goal to become the patient-friendly, new-era standard-of-care medicines, in the therapeutic area of oncology.
AI+ Ask Fintel’s AI assistant about Summit Therapeutics Inc..
Thinking about good questions…
Basic Stats
The Factor Analysis chart (below right) shows a view of Summit Therapeutics Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 82.58 MM |
| Earnings Date | |
| EPS (TTM) | -0.70 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.05 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.72 |
| ROE | -0.89 |
| ROIC | -1.41 |
| CROIC | 0.07 |
| OCROIC | -1.29 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 3.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Summit Therapeutics Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-09-08 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-09-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-09-03 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-08-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-23 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2025-04-25 | Jefferies | Buy | Buy | Maintains |
| 2025-03-12 | Evercore ISI Group | Outperform | Initiate | |
| 2025-02-28 | Goldman Sachs | Buy | Initiate | |
| 2025-02-25 | Citizens Capital Markets | Market Outperform | Market Outperform | Reiterate |
| 2025-02-25 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-08 | Truist Securities | Buy | Initiate | |
| 2024-12-11 | Wells Fargo | Overweight | Initiate | |
| 2024-12-06 | Jefferies | Buy | Initiate | |
| 2024-11-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-04 | JMP Securities | Market Outperform | Initiate | |
| 2024-10-31 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-10-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-27 | Citigroup | Buy | Neutral | Downgrade |
| 2024-09-25 | Stifel | Buy | Buy | Maintains |
| 2024-09-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-16 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-09-09 | Citigroup | Buy | Buy | Maintains |
| 2024-09-09 | Stifel | Buy | Buy | Maintains |
| 2024-09-09 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-09-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-12 | HC Wainwright & Co. | Buy | Initiate | |
| 2024-06-03 | Stifel | Buy | Buy | Maintains |
| 2024-05-31 | Citigroup | Buy | Buy | Maintains |
| 2024-05-07 | Citigroup | Buy | Initiate | |
| 2024-03-26 | Stifel | Buy | Initiate | |
| 2020-11-18 | HC Wainwright & Co. | Buy | Neutral | Downgrade |
| 2020-03-19 | H.C. Wainwright | Buy | Initiate | |
| 2018-06-28 | Janney Capital | Buy | Neutral | Downgrade |
| 2018-06-27 | SunTrust Robinson Humphrey | Buy | Hold | Downgrade |
| 2018-05-02 | Janney Capital | Buy | Initiate | |
| 2018-02-13 | BTIG Research | Buy | Initiate | |
| 2018-01-26 | Oppenheimer | Outperform | Outperform | Maintains |
| 2018-01-04 | SunTrust Robinson Humphrey | Buy | Initiate | |
| 2016-09-16 | H.C. Wainwright | Buy | Initiate | |
| 2016-06-21 | Janney Capital | Buy | Initiate | |
| 2016-02-01 | Canaccord Genuity | Buy | Initiate | |
| 2015-04-02 | JMP Securities | Outperform | Initiate | |
| 2015-03-30 | Needham | Buy | Initiate | |
| 2025-03-26 | Citigroup | Neutral | Buy | Upgrade |
| 2025-07-01 | UBS | Buy | Initiate | |
| 2025-07-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-05-02 | Goldman Sachs | Buy | Buy | Maintains |
| 2025-08-12 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-03-21 | Cantor Fitzgerald | Overweight | Initiate | |
| 2025-04-28 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-09-04 | Guggenheim | Buy | Initiate | |
| 2025-08-19 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-08-19 | Piper Sandler | Neutral | Initiate | |
| 2025-08-27 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-09-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-06-11 | Leerink Partners | Underperform | Initiate | |
| 2025-06-02 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
